Results 221 to 230 of about 138,704 (292)

Synthesis of inhibitors of histone deacetylase

, 2009
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents

Current Medicinal Chemistry, 2020
Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells.
Loredana Cappellacci, Riccardo Petrelli, Diego Romano Perinelli   +2 more
exaly   +2 more sources

Anticancer activities of histone deacetylase inhibitors

Nature Reviews Drug Discovery, 2006
Ricky Johnstone, Johnstone Ricky W
exaly   +2 more sources

Recent histone deacetylase inhibitors in cancer therapy

Cancer, 2023
Cancer metastasis increases the complexity of the disease and escalates patient mortality. Traditional chemotherapy has been associated with low efficacy and marked side effects.
Roza Parveen, Divya Harihar, B. Chatterji   +2 more
semanticscholar   +1 more source

Strategies To Design Selective Histone Deacetylase Inhibitors

ChemMedChem, 2021
This review classifies drug‐design strategies successfully implemented in the development of histone deacetylase (HDAC) inhibitors, which have many applications including cancer treatment. Our focus is on especially demanded selective HDAC inhibitors and
Jelena Melesina, C. V. Simoben, Lucas Praetorius, Emre F. Bülbül, D. Robaa, W. Sippl   +5 more
semanticscholar   +1 more source

Inhibitors of histone deacetylase as antitumor agents: A critical review

Bioorganic Chemistry, 2016
M J Nanjan, M J N Chandrasekar
exaly   +2 more sources

Histone deacetylase inhibitors

European Journal of Medicinal Chemistry, 2005
AbstractFor Abstract see ChemInform Abstract in Full Text.
BRESSI JEROME C, GANGLOFF ANTHONY R, KWOK LILY   +2 more
openaire   +6 more sources

Histone Deacetylase Inhibitors

ChemInform, 2003
AbstractFor Abstract see ChemInform Abstract in Full Text.
Thomas A, Miller, David J, Witter, Sandro, Belvedere   +2 more
openaire   +2 more sources

Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.

European journal of medicinal chemistry, 2020
Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers. HDAC3 inhibitors are effective for the treatment of cancers,
Rajat Sarkar, S. Banerjee, S. Amin, N. Adhikari, T. Jha   +4 more
semanticscholar   +1 more source